Eli Lilly’s Retevmo Phase 3 Trial in 151 Patients Cuts Recurrence Risk
Eli Lilly’s Phase 3 LIBRETTO-432 trial of Retevmo in 151 early-stage RET fusion-positive NSCLC patients showed a statistically significant reduction in recurrence or death risk and confirmed a safety profile consistent with prior studies. Detailed data will be presented at an upcoming medical congress.
1. Phase 3 Trial Outcomes
The LIBRETTO-432 study enrolled 151 early-stage RET fusion-positive NSCLC patients to receive selpercatinib or placebo. Treatment with selpercatinib produced a statistically significant improvement in event-free survival and markedly reduced the risk of disease recurrence or death.
2. Safety Profile Confirmation
Selpercatinib’s overall safety profile in this adjuvant setting matched observations from prior trials, with no new adverse events reported. The consistency of tolerability supports its use in earlier disease stages.
3. Upcoming Data Presentation
Eli Lilly plans to present full trial results at an upcoming medical congress, where detailed efficacy and safety data will be shared. Investors will gain access to hazard ratios and subgroup analyses at that time.
4. Market and Revenue Implications
These positive results could accelerate regulatory review and expand the addressable market for Retevmo in early-stage lung cancer. Analysts project potential revenue growth in oncology sales, which may boost future earnings forecasts and stock valuation.